Duke Cancer Institute

Oncologists recommend waiting for PD-L1 test results before initiating treatment in metastatic NSCLC patients without visceral crisis, as PD-L1 status guides immunotherapy selection.

A recent study suggests active monitoring may be a safe alternative to standard treatment for low-risk ductal carcinoma in situ (DCIS).

Researchers have identified the NLRP3 inflammasome as a key driver of hyper-progression in melanoma patients treated with checkpoint inhibitors.

• Dual immunotherapy or chemoimmunotherapy may offer improved outcomes for NSCLC patients with KRAS/STK11 mutations compared to single-agent PD-L1 inhibitors. • AXL inhibitors are being investigated in combination with chemotherapy and pembrolizumab to overcome STK11 mutation-related resistance in NSCLC. • Retrospective analyses of phase 3 trials suggest potential benefits of CTLA-4 inhibitors in STK11-mutant, PD-L1-negative NSCLC when combined with chemoimmunotherapy. • Clinical trials are exploring novel treatment combinations to address the challenges posed by concurrent KRAS and STK11 mutations in NSCLC.

Estrogen has been found to promote tumor growth in estrogen receptor-negative breast cancers and other cancers like melanoma and colon cancer by suppressing the immune system.

Mirvetuximab soravtansine (MIRV) demonstrates a 51.9% overall response rate in patients with platinum-sensitive ovarian cancer (PROC) in the PICCOLO trial.

A phase one study of a dendritic cell vaccine combined with intensified temozolomide showed promising survival benefits in glioblastoma patients.